Cheng Li - I Mab Chief Officer

IMAB Stock  USD 1.00  0.06  5.66%   

Insider

Cheng Li is Chief Officer of I Mab
Age 40
Address 2440 Research Boulevard, Rockville, MD, United States, 20850
Phone240 745 6330
Webhttps://ir.i-mabbiopharma.com

I Mab Management Efficiency

The company has return on total asset (ROA) of (0.2925) % which means that it has lost $0.2925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7172) %, meaning that it created substantial loss on money invested by shareholders. I Mab's management efficiency ratios could be used to measure how well I Mab manages its routine affairs as well as how well it operates its assets and liabilities. As of December 12, 2024, Return On Tangible Assets is expected to decline to -0.59. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, I Mab's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 5.2 B, whereas Non Current Assets Total are forecasted to decline to about 262.5 M.
I Mab currently holds 18.89 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. I Mab has a current ratio of 7.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about I Mab's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MBA MBAInozyme Pharma
65
Adam LevyZentalis Pharmaceuticals Llc
N/A
Madan JagasiaIovance Biotherapeutics
N/A
Melissa MBAZentalis Pharmaceuticals Llc
45
Mike PreighDay One Biopharmaceuticals
N/A
Mikhail PapisovMersana Therapeutics
N/A
PharmD ChiodinDay One Biopharmaceuticals
N/A
Ronald EvansSyndax Pharmaceuticals
75
Keith CPASyndax Pharmaceuticals
53
Carla PoulsonMersana Therapeutics
N/A
Henric BjarkeInozyme Pharma
57
Kimberly MDZentalis Pharmaceuticals Llc
55
Alexander NolteSyndax Pharmaceuticals
51
Esq JDIovance Biotherapeutics
48
William CiambroneSarepta Therapeutics
60
Friedrich MDIovance Biotherapeutics
57
Michael DownesSyndax Pharmaceuticals
N/A
Michael MBASyndax Pharmaceuticals
53
Alvin PharmdPuma Biotechnology
71
Howard MBAIovance Biotherapeutics
64
Stefan RileyInozyme Pharma
N/A
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company was founded in 2014 and is headquartered in Shanghai, the Peoples Republic of China. I-Mab ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 378 people. I Mab (IMAB) is traded on NASDAQ Exchange in USA. It is located in 2440 Research Boulevard, Rockville, MD, United States, 20850 and employs 34 people. I Mab is listed under Biotechnology category by Fama And French industry classification.

Management Performance

I Mab Leadership Team

Elected by the shareholders, the I Mab's board of directors comprises two types of representatives: I Mab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IMAB. The board's role is to monitor I Mab's management team and ensure that shareholders' interests are well served. I Mab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, I Mab's outside directors are responsible for providing unbiased perspectives on the board's policies.
CLP Esq, COO CFO
Louie MD, Interim Officer
Richard MBA, COO CFO
Weiming Tang, Executive Officer
Jerry Wang, CoFounder Officer
Cheng Li, Chief Officer
Skelton Joseph, Chief Officer
John MD, Chief Officer
XiYong MBA, Director CEO
Tianyi Zhang, Vice Relations
Raj Kannan, CEO Director
Jingwu MD, Founder Chairman
Ivan Zhu, Chief Officer
Min Yin, Senior Operations
Phillip MD, Chief Officer
Gigi Feng, Chief Officer
Fernando Salles, Senior Development
Claire Xu, Head site
Tyler Ehler, Senior Relations

IMAB Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is I Mab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether I Mab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of I Mab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of I Mab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on I Mab Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.16)
Revenue Per Share
0.043
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.29)
Return On Equity
(0.72)
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.